Optimising the selection of candidates for neoadjuvant chemotherapy amongst patients with node-positive penile squamous cell carcinoma.

导出 LinkOut

翻译打印收藏纠错

作者： Marco,Bandini ^[1] ; Maarten,Albersen ^[2] ; Juan,Chipollini ^[3] ; Filippo,Pederzoli ^[1] ; Yao,Zhu ^[4] ; Ding-Wei,Ye ^[4] ; Antonio A,Ornellas ^[5] ; Nick,Watkin ^[6] ; Michael,Ager ^[6] ; Oliver W,Hakenberg ^[7] ; Axel,Heidenreich ^[8] ; Daniele,Raggi ^[9] ; Mario,Catanzaro ^[9] ; Friederike,Haidl ^[8] ; Elio,Mazzone ^[1] ; Laura,Marandino ^[9] ; Alberto,Briganti ^[1] ; Francesco,Montorsi ^[1] ; Mounsif,Azizi ^[3] ; Philippe E,Spiess ^[3] ; Andrea,Necchi ^[7]

作者单位： Unit of Urology, Urological Research Institute (URI), IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Milan, Italy. ^[1] University Hospitals Leuven, Leuven, Belgium. ^[2] Moffitt Cancer Center and Research Institute, Tampa, FL, USA. ^[3] Fudan University Shanghai Cancer Center, Shanghai, China. ^[4] Hospital Mário Kröeff and Brazilian Cancer Institute, Rio de Janeiro, Brazil. ^[5] NHS Foundation Trust, St. George's University Hospitals, London, UK. ^[6] University Hospital Rostock, Rostock, Germany. ^[7] Universitätsklinikum Köln, Köln, Germany. ^[8] Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy. ^[9]

关键词 neoadjuvant chemotherapy patient selection penile cancer regression-tree squamous cell carcinoma